Skip to main content
Pay Bill Portals

EORTC2129-BCG: elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (Treat ctDNA trial).

Published Date

Ignatiadis M, Saloustros E, Joaquim A, et al. ASCO Annual Meeting 2025, Chicago, IL. M

Download PDF